Antonella V. Rossi

Bari, 70124, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Assessment of Transitioning from High-Potency to Low-Potency Inhibitors in Chronic Myeloid Leukemia (CML) Patients: The Downgrading-Impact (D-IMPACT) Project.

Journal: Cancers

Published: April 08, 2026

Unmet needs and quality of life burden in chronic myeloid leukemia: results from a nationwide Italian real-world survey.

Unmet needs and quality of life burden in chronic myeloid leukemia: results from a nationwide Italian real-world survey.

Journal: Frontiers in oncology

Published: April 03, 2026

Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies.

Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies.

Journal: Vaccines

Published: March 10, 2025

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.

Journal: Leukemia

Published: March 04, 2025

The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.

The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 08, 2023

Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event.

Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event.

Journal: Leukemia research

Published: November 09, 2022

SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance.

SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance.

Journal: HemaSphere

Published: August 31, 2022

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study).

Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study).

Journal: Frontiers in oncology

Published: December 14, 2021

Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.

Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.

Journal: British journal of haematology

Published: October 19, 2021

Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.

Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.

Journal: Acta oncologica (Stockholm, Sweden)

Published: September 09, 2021

Occurrence of chronic myeloid leukemia in a patient with CDC73 gene deletion: "Chance or Causality?"

Occurrence of chronic myeloid leukemia in a patient with CDC73 gene deletion: "Chance or Causality?"

Journal: International journal of laboratory hematology

Published: March 19, 2021

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.

Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study.

Journal: Cancer medicine

Published: August 19, 2020

Showing 1-12 of 26

Last Updated: 09/26/2026